Log in

Novocure Stock Price, Forecast & Analysis (NASDAQ:NVCR)

$90.43
+1.99 (+2.25 %)
(As of 11/21/2019 05:25 AM ET)
Today's Range
$88.40
Now: $90.43
$91.07
50-Day Range
$68.12
MA: $76.71
$90.42
52-Week Range
$28.15
Now: $90.43
$98.70
Volume1.28 million shs
Average Volume726,276 shs
Market Capitalization$8.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$248.07 million
Book Value$1.21 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$8.95 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.07. The medical equipment provider had revenue of $92.06 million for the quarter, compared to analyst estimates of $87.12 million. Novocure had a negative return on equity of 18.45% and a negative net margin of 8.43%. The business's quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.13) earnings per share. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

What price target have analysts set for NVCR?

6 brokers have issued 1 year target prices for Novocure's stock. Their forecasts range from $50.00 to $97.00. On average, they anticipate Novocure's stock price to reach $79.40 in the next year. This suggests that the stock has a possible downside of 12.2%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Has Novocure been receiving favorable news coverage?

News articles about NVCR stock have trended positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novocure earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Novocure.

Are investors shorting Novocure?

Novocure saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 3,670,000 shares, a drop of 8.9% from the September 30th total of 4,030,000 shares. Based on an average daily volume of 762,600 shares, the short-interest ratio is currently 4.8 days. Currently, 4.6% of the shares of the company are short sold. View Novocure's Current Options Chain.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by many different of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (0.83%), Carillon Tower Advisers Inc. (0.58%), TimesSquare Capital Management LLC (0.49%), Rhenman & Partners Asset Management AB (0.35%), California Public Employees Retirement System (0.19%) and C WorldWide Group Holding A S (0.17%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Peregrine Capital Management LLC, C WorldWide Group Holding A S, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Empowered Funds LLC, Janney Montgomery Scott LLC and SG Americas Securities LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

Which major investors are buying Novocure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., State of New Jersey Common Pension Fund D, Kornitzer Capital Management Inc. KS, California Public Employees Retirement System, Great Lakes Advisors LLC, Tuttle Tactical Management and W.E. Donoghue & Co. LLC. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $90.43.

How big of a company is Novocure?

Novocure has a market capitalization of $8.95 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  739
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel